Evidence map›Paper›PMID 40023492›Full record

ArticleThe Journal of molecular diagnostics : JMD2025

Detection of Gene Fusions and Rearrangements in Formalin-Fixed, Paraffin-Embedded Solid Tumor Specimens Using High-Throughput Chromosome Conformation Capture.

Kristyn Galbraith, Jamin Wu, Kristin Sikkink, Hussein Mohamed, Derek Reid, Michelle Perez-Arreola, Jon-Matthew Belton, Sofia Nomikou, Shadi Melnyk, Yiying Yang and 10 more

Abstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kristyn GalbraithDepartment of Pathology, NYU Langone Health, and NYU Grossman School of Medicine, New York, New York. Electronic address: kgalbrai@uw.edu.
Jamin WuDepartment of Pathology, NYU Langone Health, and NYU Grossman School of Medicine, New York, New York.
Kristin SikkinkArima Genomics, Inc., Carlsbad, California.
Hussein MohamedDepartment of Pathology, NYU Langone Health, and NYU Grossman School of Medicine, New York, New York.
Derek ReidArima Genomics, Inc., Carlsbad, California.
Michelle Perez-ArreolaArima Genomics, Inc., Carlsbad, California.
Jon-Matthew BeltonArima Genomics, Inc., Carlsbad, California.
Sofia NomikouArima Genomics, Inc., Carlsbad, California.
Shadi MelnykArima Genomics, Inc., Carlsbad, California.
Yiying YangDepartment of Pathology, NYU Langone Health, and NYU Grossman School of Medicine, New York, New York.
Benjamin L LiechtyDepartment of Pathology, Weill Cornell School of Medicine, New York, New York.
George JourDepartment of Pathology, NYU Langone Health, and NYU Grossman School of Medicine, New York, New York.
Aristotelis TsirigosDepartment of Pathology, NYU Langone Health, and NYU Grossman School of Medicine, New York, New York; Division of Precision Medicine, Department of Medicine, NYU School of Medicine, New York, New York; Applied Bioinformatics Laboratories, NYU School of Medicine, New York, New York.
David J HermelScripps Clinic/Scripps Cancer Center, La Jolla, California.
Alyssa BeckMoores Cancer Center, University of California San Diego, San Diego, California.
Darren SigalScripps Clinic/Scripps Cancer Center, La Jolla, California.
Nathan A DahlMorgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.
Rajeev VibhakarMorgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.
Anthony SchmittArima Genomics, Inc., Carlsbad, California.
Matija SnuderlDepartment of Pathology, NYU Langone Health, and NYU Grossman School of Medicine, New York, New York; Brain and Spine Tumor Center, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York; Department of Pathology, NYU Langone Health, and NYU Grossman School of Medicine, New York, New York. Electronic address: matija.snuderl@nyulangone.org.

Funding

Developing a kit-based research use only (RUO) translocation assay for deployment as a lab developed test (LDT) toward changing outcomes for patients with driver-negative tumorsR44CA247185 · NCI · ARIMA GENOMICS, INC. · PI SELVARAJ, SIDDARTH · 2020 to 2024
$6.0M
Inducing Neural Maturation in Medulloblastoma by Targeting EZH2R01NS122987 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAJU, PRAVEEN B., SNUDERL, MATIJA · 2022 to 2025
$2.8M
NCI NIH HHS R44 CA247185NINDS NIH HHS R01 NS122987
6 · The paper itself

Abstract

Chromosomal structural variants (SVs) are major contributors to cancer development. Although multiple methods exist for detecting SVs, they are limited in throughput, such as fluorescent in situ hybridization and targeted panels, and use RNA, which degrades in formalin-fixed, paraffin-embedded (FFPE) blocks and is unable to detect SVs that do not produce a fusion transcript. High-throughput chromosome conformation capture (Hi-C) is a DNA-based next-generation sequencing (NGS) method that preserves the spatial conformation of the genome, capturing long-range genetic interactions and SVs. Herein, a retrospective study analyzing 71 FFPE specimens from 10 different solid tumors was performed. Results showed high concordance (98%) with clinical fluorescent in situ hybridization and RNA NGS in detecting known SVs. Furthermore, Hi-C provided insight into the mechanism of SV formation, including chromothripsis and extrachromosomal DNA, and detected rearrangements between genes and regulatory regions, all of which are undetectable by RNA NGS. Lastly, SVs were detected in 71% of cases in which previous clinical methods failed to identify a driver. Of these, 14% were clinically actionable based on current medical guidelines, and an additional 14% were not in medical guidelines but involve targetable biomarkers. Current data suggest that Hi-C is a robust and accurate method for genome-wide SV analyses from FFPE tissue and can be incorporated into current clinical NGS workflows.

Indexed as

Gene FusionGene RearrangementHigh-Throughput Nucleotide SequencingNeoplasmsFormaldehydeHumansIn Situ Hybridization, FluorescenceParaffin EmbeddingRetrospective StudiesTissue FixationFormaldehyde

Identifiers

PMID40023492
PMCPMC12057137

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.